Must not have received investigational therapy within  days of entry onto this study
Patients should have been off other investigational therapy for one month prior to receiving treatment on this study
TREATMENT: Patients should have been off other investigational therapy for one month prior to entry in this study
Prior investigational therapy (medications or devices) within  weeks of treatment.
Patients should have been off other investigational therapy for one month prior to entry in this study
Patients should have been off other investigational therapy for one month prior to receiving treatment on this study
INCLUSION - INFUSION: Patients should have been off other investigational therapy for  weeks prior to entry in this study
Other investigational therapy: at least two weeks since any other investigational therapy
Prior systemic chemotherapy or therapy with one of the investigational agents within  month prior to enrollment
Patients who had therapy with one of the investigational agents more than  month prior to enrollment in whom tumor genotyping show assignment to the same investigational agent
Patients should have been off other investigational therapy for one month prior to entry in this study
off other investigational therapy for one month prior to entry in this study.
No other investigational antitumor therapy for one month prior to entry in this study
Treatment with investigational therapy within  days prior to randomisation
No prior investigational therapy within  weeks prior to study enrollment
Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within four weeks prior to study entry
Treatment with radiation therapy, surgery, or investigational therapy within one month prior to registration
Participant may have received prior investigational therapy (including immune therapy)
Other investigational therapy (within  days of Study Day ).
Investigational therapy within  weeks of screening
TREATMENT: Patients should have been off other investigational therapy for one month prior to entry in this study
Recent Investigational therapy
Patients who are receiving concurrent investigational therapy or who have received investigational therapy within  days of the first scheduled day of protocol treatment
Patients should have been off other investigational therapy for  weeks prior to entry in this study
Treated with any investigational therapy within  weeks of the first dose of study treatment.
Prior investigational therapy within the past  days.
Investigational therapy within  weeks.
Investigational therapy within  weeks of Screening.
Investigational therapy within  weeks prior to CMB dosing
Investigational therapy within  weeks prior to CMB dosing
Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within  days prior to study entry.
Investigational therapy within  weeks prior to LV dosing.
Any investigational therapy within  days prior to the first dose of IP.
Any investigational therapy within  days prior to the first dose of IP.
Concurrent investigational therapy or investigational therapy within  weeks of start of afatinib therapy
Investigational therapy within  weeks prior to G dosing
Investigational therapy within  weeks of Screening.
Treatment with investigational therapy within  weeks of study treatment
AT THE TIME OF INFUSION: Off investigational therapy for  weeks prior to study entry
Other investigational therapy (not included above) within  weeks of randomization
Ongoing treatment with any other investigational therapy
Subjects who received any investigational medication, prior local therapy for pancreas cancer , or any significant change in treatment within  month prior to screening
Concurrent investigational treatment, chemotherapy, or targeted therapy; prior chemotherapy, hormonal therapy, targeted therapy, and investigational agents are allowed but all toxicities grade >=  must have resolved by the time of study commencement (except alopecia)
Subject may have received prior investigational therapy (including immune therapy)
Patients should have been off other investigational antiviral or antitumor therapy for one month prior to entry in this study
Ongoing investigational treatment
Prior to study treatment administration, at least  days must have elapsed since the subject's prior investigational or non-investigational systemic therapy, or any major surgery, and at least  days since prior radiotherapy.
Any investigational therapy in the past  days
Investigational therapy less than one month prior to study entry
Ongoing treatment with any other investigational therapy
An investigational therapy.
Investigational therapy or any other therapy =<  days before first study treatment
Has received investigational therapy within  weeks prior to randomization
Patient is receiving or plans to receive other investigational therapy during study.
Patients should have been off other investigational therapy for one month prior to entry in this study
